Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.

[1]  A. Schmermund,et al.  Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. , 2016, Journal of the American College of Cardiology.

[2]  Michael J Lipinski,et al.  Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis. , 2016, JACC. Cardiovascular interventions.

[3]  P. Teirstein,et al.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.

[4]  P. Fitzgerald,et al.  Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. , 2015, American heart journal.

[5]  S. Achenbach,et al.  Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  A. Colombo,et al.  Procedural feasibility and clinical outcomes in propensity-matched patients treated with bioresorbable scaffolds vs new-generation drug-eluting stents. , 2015, The Canadian journal of cardiology.

[7]  Antonio Colombo,et al.  Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  Ryo Torii,et al.  Incomplete Stent Apposition Causes High Shear Flow Disturbances and Delay in Neointimal Coverage as a Function of Strut to Wall Detachment Distance: Implications for the Management of Incomplete Stent Apposition , 2014, Circulation. Cardiovascular interventions.

[9]  R. Virmani,et al.  Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. , 2013, JACC. Cardiovascular interventions.

[10]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[11]  Seung‐Jung Park,et al.  Comparison of Resolute Zotarolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients With De Novo Long Coronary Artery Lesions: A Randomized LONG-DES IV Trial , 2012, Circulation. Cardiovascular Interventions.

[12]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[13]  I. Seong,et al.  Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. , 2011, JACC. Cardiovascular interventions.

[14]  L. Sim,et al.  Long-term outcomes after coronary bare-metal-stent and drug-eluting-stent implantations: a ‘real-world’ comparison among patients with diabetes with diffuse small vessel coronary artery disease , 2011, Coronary artery disease.

[15]  Rosaire Mongrain,et al.  Evaluation of the effect of stent strut profile on shear stress distribution using statistical moments , 2009, Biomedical engineering online.

[16]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[17]  D. Berman,et al.  The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. , 2007, The American journal of cardiology.

[18]  Seung‐Jung Park,et al.  Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. , 2006, The American journal of cardiology.

[19]  K. Seung,et al.  Comparison of sirolimus‐eluting stent, paclitaxel‐eluting stent, and bare metal stent in the treatment of long coronary lesions , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[21]  G. Stone,et al.  Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. , 2002, Journal of the American College of Cardiology.

[22]  C. Di Mario,et al.  Stented segment length as an independent predictor of restenosis. , 1999, Journal of the American College of Cardiology.

[23]  M. Hadamitzky,et al.  Influence of lesion length on restenosis after coronary stent placement. , 1999, The American journal of cardiology.